Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phylex SARS-CoV-2 mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- Phylex BioSciences
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Phylex SARS-CoV-2 mRNA vaccine is a second-generation COVID-19 vaccine candidate developed by Phylex BioSciences. The vaccine utilizes a proprietary mRNA self-assembling nanoparticle technology, where the mRNA sequence encodes a protein that spontaneously forms a nanoparticle displaying 60 copies of the SARS-CoV-2 receptor binding domain (RBD). This multivalent display is designed to mimic the virus's geometry and symmetry, potentially eliciting more potent and durable neutralizing antibody responses compared to first-generation mRNA vaccines. Preclinical data, generated in collaboration with the Pasteur Institute and the University of Bern, showed robust protection against variants of concern, including Delta and Omicron, in transgenic mouse models. The candidate is currently in preclinical development.
- Other names
- Phylex COVID-19 vaccinePhylex mRNA nanoparticle vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Phylex SARS-CoV-2 mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phylex SARS-CoV-2 mRNA vaccine.